Holen Sie sich die Stockscreener-App
41.52
5.05%
-2.21
Vorhandelsmarkt:
40.85
-0.67
-1.61%
Schlusskurs vom Vortag:
$43.73
Offen:
$44
24-Stunden-Volumen:
43.16M
Relative Volume:
1.53
Marktkapitalisierung:
$9.04B
Einnahmen:
$1.78B
Nettoeinkommen (Verlust:
$164.40M
KGV:
60.17
EPS:
0.69
Netto-Cashflow:
$236.51M
1W Leistung:
-5.76%
1M Leistung:
-24.18%
6M Leistung:
-16.07%
1J Leistung:
+77.28%
1-Tages-Spanne:
$39.84
$44.00
1-Wochen-Bereich:
$39.84
$48.34
52-Wochen-Spanne:
$19.15
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Vergleichen Sie HIMS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
41.52 | 9.96B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
119.56 | 53.10B | 9.40B | 2.65B | 2.22B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.64 | 42.93B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.41 | 41.46B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.46 | 28.22B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
454.00 | 19.27B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Shares Tumble as Profit Miss Overshadows Revenue Growth - AD HOC NEWS
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced - Stocktwits
JPMorgan Chase & Co. Expands Holdings in Hims & Hers Health Inc. - GuruFocus
GLP-1 price cuts limit Hims advantage, says Needham - TipRanks
Sell Recommendation for Hims & Hers Health Amid Competitive Pricing Pressures and Projected Decline - TipRanks
TrumpRx GLP-1 pricing ‘less bad than feared’ for Hims & Hers, says Citi - TipRanks
Understanding Momentum Shifts in (HIMS) - news.stocktradersdaily.com
Hims & Hers Health (HIMS) Looks to Turn GLP-1 Hype Into Health Empire - MSN
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? - Stocktwits
1 Growth Stock to Stash and 2 We Ignore - The Globe and Mail
Hims & Hers Health Q3 2025 Earnings: Revenue Jumps 49%News and Statistics - IndexBox
Why Are Hims & Hers Health (HIMS) Shares Soaring Today - TradingView
Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract - Yahoo Finance
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results - sharewise.com
Analysts Issue Forecasts for HIMS Q3 Earnings - MarketBeat
Hims & Hers: GLP-1 Partnership Could Unlock Value (NYSE:HIMS) - Seeking Alpha
Mission Wealth Management LP Acquires Shares of 10,300 Hims & Hers Health, Inc. $HIMS - MarketBeat
Teacher Retirement System of Texas Purchases 6,925 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Arkadios Wealth Advisors Acquires New Shares in Hims & Hers Health, Inc. $HIMS - MarketBeat
Promising Healthcare Stocks To Watch NowNovember 2nd - MarketBeat
Potential Wegovy Partnership Could Transform Hims & Hers Growth Trajectory - AD HOC NEWS
Hims & Hers Health, Inc. Reports Strong Growth and Strategic Optimism - TipRanks
White House nears deal to lower prices for weight loss drugs Wegovy and Zepbound - AOL.com
Hims & Hers gains as analysts welcome talks with Novo for Wegovy sales - MSN
Best Healthcare Stocks To Follow TodayNovember 4th - MarketBeat
Novo Nordisk’s Wegovy could soon have a new sales outlet in the U.S. - MSN
OMCL vs. HIMS: Which Stock Is the Better Value Option? - sharewise.com
HIMS Q3 Deep Dive: Personalized Offerings and Strategic Expansion Shape Telehealth Growth - The Globe and Mail
Hims & Hers Eyes Major Weight-Loss Breakthrough With Potential Novo Nordisk Wegovy Deal - Yahoo Finance
Hims shares rise on talks to offer Novo’s new obesity pill - The Detroit News
Deutsche Bank Adjusts Hims & Hers Health Price Target to $42 From $48, Maintains Hold Rating - MarketScreener
Hims & Hers rises after Q3 revenue beat - TradingView
BTIG Research Reiterates Buy Rating for Hims & Hers Health (NYSE:HIMS) - MarketBeat
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00 - MarketBeat
Hims and Hers tops revenue estimates as telehealth provider attracts more users - MSN
Earnings live: Palantir stock rises modestly on strong results, Hims & Hers stock surges - Yahoo Finance
Hims Shares Rise on Talks to Offer Novo’s New Obesity Pill - Bloomberg
Biggest stock movers Tuesday: PLTR, SRPT, and more - MSN
Hims & Hers Plunges After Novo Split, Eyes Global Push - Value The Markets
Hims & Hers Stock (HIMS) Soars on Potential Deal to Offer Novo Nordisk’s Wegovy - TipRanks
Hims & Hers projects over $6.5B revenue by 2030 as global expansion and diagnostics strategy accelerates - MSN
Decoding Hims & Hers Health Inc (HIMS): A Strategic SWOT Insight - GuruFocus
Hims & Hers Health Inc (HIMS) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
Hims & Hers Health Reports Strong Q3 2025 Growth - TipRanks
Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets - Stocktwits
Palantir, Kimberly-Clark, Hims & Hers, Navitas And Cipher Mining: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Key facts: Novo Nordisk Q3 revenue up 9.4%; bids $8.5B for Metsera; Hims launches semaglutide - TradingView
Hims Hers (HIMS) Q3 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Hims & Hers Health Q3 2025 misses EPS, stock rebounds - Investing.com Philippines
Live: Hims & Hers Earnings Coverage - 24/7 Wall St.
Novo Nordisk’s weight-loss drug Wegovy could soon have a new sales outlet in the U.S. - MarketWatch
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.37%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):